« Back to Record
Citation APA

Saglio, G., Kim, S.-S., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R., Kantarjian, H. M., & ENESTnd Investigators, (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. The New England journal of medicine, 362(24), 2251-2259. doi:10.1056/NEJMoa0912614


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/118242

Saglio, G., Kim, S.-S., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R., Kantarjian, H. M., & ENESTnd Investigators, (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. The New England journal of medicine, 362(24), 2251-2259. doi:10.1056/NEJMoa0912614